BPI
ZVRA icon

BFC Planning, Inc.’s Zevra Therapeutics ZVRA Stock Holding History

BFC Planning, Inc.’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.5K Hold
1,500
– – ﹤0.01% 1976
2026
Q1 		$14K Hold
1,500
– – ﹤0.01% 1878
2025
Q4 		$13.4K Hold
1,500
– – ﹤0.01% 1937
2025
Q3 		$14.3K Hold
1,500
– – ﹤0.01% 1744
2025
Q2 		$13.2K Hold
1,500
– – ﹤0.01% 1684
2025
Q1 		$11.2K Hold
1,500
– – ﹤0.01% 1717
2024
Q4 		$12.5K Buy
+1,500
New +$12.8K ﹤0.01% 1661

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BFC Planning, Inc.'s ZVRA Position: Q2 2026 in Review

BFC Planning, Inc. held its Zevra Therapeutics (ZVRA) position steady in Q2 2026 at 1,500 shares worth $21.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1976.

BFC Planning, Inc. first reported a position in ZVRA in Q4 2024 and has held it in 7 quarters since. 159 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • BFC Planning, Inc. held 1,500 shares of Zevra Therapeutics worth $21.5K as of Q2 2026.
  • BFC Planning, Inc. left its Zevra Therapeutics share count unchanged in Q2 2026.
  • Zevra Therapeutics made up ﹤0.01% of BFC Planning, Inc.'s portfolio in Q2 2026, its #1976 holding.
  • BFC Planning, Inc. first reported a position in Zevra Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 159 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on BFC Planning, Inc.'s 13F filing for Q2 2026, filed 29 Oct 2026.